Clinical and Translational Research
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 314-330
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.314
Table 3 Basic information of patients expressing BECN1, n (%)
CharacteristicCategoryLow expression of BECN1, n = 322High expression of BECN1, n = 322P value
T stageT111 (1.7)9 (1.4)0.599
T258 (9.0)53 (8.3)
T3210 (32.8)226 (35.3)
T441 (6.4)33 (5.1)
N stageN0179 (28.0)189 (29.5)0.523
N176 (11.9)77 (12.0)
N265 (10.2)54 (8.4)
M stageM0246 (43.6)229 (40.6)0.496
M142 (7.4)47 (8.3)
Primary therapy outcomePD16 (5.1)17 (5.4)0.775
SD2 (0.6)3 (1.0)
PR10 (3.2)6 (1.9)
CR128 (41)130 (41.7)
SexFemale149 (23.1)152 (23.6)0.874
Male173 (26.9)170 (26.4)
CEA level≤ 5126 (30.4)135 (32.5)0.477
> 568 (16.4)86 (20.7)
Perineural invasionNo58 (24.7)117 (49.8)0.310
Yes15 (6.4)45 (19.1)
Lymphatic invasionNo160 (27.5)190 (32.6)0.014
Yes131 (22.5)101 (17.4)
History of colon polypsNo177 (31.9)200 (36)< 0.001
Yes113 (20.4)65 (11.7)
Neoplasm typeColon adenocarcinoma234 (36.3)244 (37.9)0.417
Rectum adenocarcinoma88 (13.7)78 (12.1)
Age in yr, median (IQR)69.0 (62.0, 77.0)65.5 (55.3, 75.0)< 0.001